×
Generation Bio Total Long-Term Assets 2020-2024 | GBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Generation Bio total long-term assets from 2020 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
View More
Generation Bio Total Long-Term Assets 2020-2024 | GBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Generation Bio total long-term assets from 2020 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.6B
Vertex Pharmaceuticals (VRTX)
$117.1B
Regeneron Pharmaceuticals (REGN)
$111.8B
Bristol Myers Squibb (BMY)
$109.9B
Gilead Sciences (GILD)
$104.8B
CSL (CSLLY)
$95.8B
GSK (GSK)
$79.5B
Alnylam Pharmaceuticals (ALNY)
$34.6B
Argenex SE (ARGX)
$32.5B
BioNTech SE (BNTX)
$28.5B
Biogen (BIIB)
$26.9B
Moderna (MRNA)
$23.5B
BeiGene (BGNE)
$22.7B
Illumina (ILMN)
$21.7B
Genmab (GMAB)
$15.5B
BioMarin Pharmaceutical (BMRN)
$12.9B
Incyte (INCY)
$12.9B
Vaxcyte (PCVX)
$12.4B
Exact Sciences (EXAS)
$12.3B
Insmed (INSM)
$12.3B
Bio-Techne Corp (TECH)
$11.7B
Sarepta Therapeutics (SRPT)
$11.3B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Legend Biotech (LEGN)
$8.7B
Roivant Sciences (ROIV)
$8.3B
Ascendis Pharma (ASND)
$8.2B
Repligen (RGEN)
$7.8B
Revolution Medicines (RVMD)
$7.7B
Halozyme Therapeutics (HALO)
$7.7B